



268 | 117 | 6
Views | CrossRef citations to date | Altmetric

Research Report

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

Brian Godman, William Shrank, Morten Andersen, Christian Berg, Iain Bishop, Thomas Burkhardt, ... [show all](#)

Pages 707-722 | Published online: 09 Jan 2014

🗨️ Cite this article 🔗 <https://doi.org/10.1586/erp.10.72>

Sample our
Bioscience
Journals



We Care About Your Privacy

We and our 907 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide," whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the ["privacy preferences"] link on the bottom of the webpage [or the floating icon on the bottom-left of the webpage, if applicable]. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

...

I Accept

Reject All

Show Purpose



differences in the utilization of generics and patent-protected PPIs and statins among Western European countries. Decreased utilization of omeprazole and simvastatin, alongside increased utilization of esomeprazole, atorvastatin and rosuvastatin, was seen in countries with limited demand-side measures to counteract commercial pressures. Prescribing restrictions, or a combination of education, prescribing targets and financial incentives, had the greatest influence on enhancing the utilization of omeprazole and simvastatin. For example, there was a threefold reduction in the utilization of atorvastatin in Austria following prescribing restrictions. Multiple demand-side interventions generally had a greater influence than single interventions, with the impact appearing additive. Multiple interventions coupled with initiatives to lower prices of generics considerably enhanced prescribing efficiency. Conclusion: this cross-national study has demonstrated considerable variation in the utilization and expenditure of PPIs and statins across Europe, providing opportunities to further improve prescribing efficiency. The '4 Es' do provide an understandable methodology to document and compare the influence of different demand-side measures, with the influence varying by their extent and intensity. Further reforms are essential given current financial pressures. Consequently, further research will concentrate on the potential to develop a scoring system to help predict the possible impact of different demand-side measures on future utilization patterns.

Keywords

cross-national



ng efficiency

Acknowledgements

The data for this study were obtained from the National Prescription Monitoring Scheme (NPMS) data for the period 2007-2012. The data were provided by the NHS Digital, London. The data were analysed by the Stockholm Health Care Services, Stockholm, Sweden. The study was funded by the Swedish Health Care Services, Stockholm, Sweden.



on of NHS
vision of the
ka Institutet,
is study was

Financing

The majority of the authors are employed directly by health authorities or health insurance agencies or are advisers to these organizations (see affiliations). Morten Andersen has received teaching grants from the Danish Association of Pharmaceutical Industries for providing education on pharmacoepidemiology. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Related Research Data

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

Source: Expert Review of Pharmacoeconomics & Outcomes Research

Prescribing Incentive Schemes

Source: Applied Health Economics and Health Policy

Economic incentives in general practice: The impact of pay-for-participation and pay-for-compliance programs on diabetes care

Source:

Ongoing

Source:

Forecast

Source:

Physician's perspective on the impact of drugs

in the

Source:

Copied from statin

Source:

Insight into holders

Source:

Copied from ion

data

Source:

Influence of what

Source:

Physicians' opinions and experiences of the Pharmaceutical Benefits Reform



Source: Scandinavian Journal of Public Health

Trends in generic prescribing and dispensing in Europe

Source: Expert Review of Clinical Pharmacology

Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply

Source: European Heart Journal

Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – are drug utilisation data comparable?

Source: European Journal of Clinical Pharmacology

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

Source: Health Policy

Patients' attitudes towards and experiences of generic drug substitution in Norway

Source: Pharmaceutisch Weekblad

Heart Protection Study

Source: The Lancet

Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003

Source: British Journal of Clinical Pharmacology

Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 French community pharmacists.

Source: Pharmacy World & Science

Gene

Source

Tier 4

Source

Impa

lower

Source

Sustit

a

So

Upda

Presc

Source

New

presc

Source

Drugs

Source: British Journal of Clinical Pharmacology



Methods of Economic Evaluation for the German Statutory Healthcare System

Source: PharmacoEconomics

Drugs, money and society.

Source: British Journal of Clinical Pharmacology

Recent National and Regional Drug Reforms in Sweden

Source: PharmacoEconomics

A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice

Source: Health Policy

Superior efficacy of new medicines?

Source: European Journal of Clinical Pharmacology

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

Source: Expert Review of Pharmacoeconomics & Outcomes Research

Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?

Source: European Heart Journal

Systematic Review of Interventions to Improve Prescribing

Source: Annals of Pharmacotherapy

Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe

Source: European Journal of Clinical Pharmacology

Soft m

Source

Contr

Source

Gettin

pract

imple

Source

S

So

Effect

gene

Source

Gettin

Source

The e

trials

Source: CMAJ



Public drug expenditure in the Republic of Ireland

Source: Expert Review of Pharmacoeconomics & Outcomes Research

Enhancing the rational use of new medicines across European health care systems

Source: European Journal of Clinical Pharmacology

Having Your Cake and Eating It

Source: PharmacoEconomics

International comparison of generic medicine prices

Source: Current Medical Research and Opinion

Variations and increase in use of statins across Europe: data from administrative databases

Source: BMJ

Effectiveness and efficiency of guideline dissemination and implementation strategies

Source: Health Technology Assessment

Simvastatin reduced mortality and vascular events in diabetes mellitus

Source: Evidence-Based Medicine

Pharmaceutical policies: effects of financial incentives for prescribers

Source: Cochrane Database of Systematic Reviews

Using clinical evidence

Source: BMJ

Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries

Source: Health Policy

The E

Source

Sector

The P

Source

Patient

Source

Germ

s

So

Use c

in Eu

Source

Polici

and f

Source

A qua

influence of cost on prescribing



Source: Social Science & Medicine

Customers' and physicians' opinions of and experiences with generic substitution during the first year in Finland

Source: Health Policy

Pharmaceutical policies: effects of financial incentives for prescribers

Source: Unknown Repository

Pharmaceutical policies: effects on rational drug use

Source: Cochrane Database of Systematic Reviews

Healthcare policies over the last 20 years: Reforms and counter-reforms

Source: Health Policy

Generic medicine pricing in Europe: current issues and future perspective

Source: Journal of Medical Economics

Experimental and quasi-experimental designs for evaluating guideline implementation strategies

Source: Family Practice

Comments on the MRC/BHF Heart Protection Study

Source: The Lancet

Informing disinvestment through cost-effectiveness modelling

Source: Applied Health Economics and Health Policy

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

Source: The Lancet

From patients' perspectives to patients' care

Source

Linkin



Relat

Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Keep up to date

Register to receive personalised research and resources by email

 Sign me up



Copyright © 2023

Accessibility

Registered
5 Howick Place

Wiley & Francis Group
a John Wiley & Sons business

